Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis.
cost-effectiveness analysis
data sharing
methodology
quality
reporting
reproducibility
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
13 02 2020
13 02 2020
Historique:
entrez:
16
2
2020
pubmed:
16
2
2020
medline:
9
3
2021
Statut:
epublish
Résumé
There has been a growing awareness of the need for rigorously and transparent reported health research, to ensure the reproducibility of studies by future researchers. Health economic evaluations, the comparative analysis of alternative interventions in terms of their costs and consequences, have been promoted as an important tool to inform decision-making. The objective of this study will be to investigate the extent to which articles of economic evaluations of healthcare interventions indexed in MEDLINE incorporate research practices that promote transparency, openness and reproducibility. This is the study protocol for a cross-sectional comparative analysis. We registered the study protocol within the Open Science Framework (osf.io/gzaxr). We will evaluate a random sample of 600 cost-effectiveness analysis publications, a specific form of health economic evaluations, indexed in MEDLINE during 2012 (n=200), 2019 (n=200) and 2022 (n=200). We will include published papers written in English reporting an incremental cost-effectiveness ratio in terms of costs per life years gained, quality-adjusted life years and/or disability-adjusted life years. Screening and selection of articles will be conducted by at least two researchers. Reproducible research practices, openness and transparency in each article will be extracted using a standardised data extraction form by multiple researchers, with a 33% random sample (n=200) extracted in duplicate. Information on general, methodological and reproducibility items will be reported, stratified by year, citation of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement and journal. Risk ratios with 95% CIs will be calculated to represent changes in reporting between 2012-2019 and 2019-2022. Due to the nature of the proposed study, no ethical approval will be required. All data will be deposited in a cross-disciplinary public repository. It is anticipated the study findings could be relevant to a variety of audiences. Study findings will be disseminated at scientific conferences and published in peer-reviewed journals.
Identifiants
pubmed: 32060160
pii: bmjopen-2019-034463
doi: 10.1136/bmjopen-2019-034463
pmc: PMC7045222
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e034463Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMJ. 2007 Oct 13;335(7623):735
pubmed: 17932167
BMJ. 1996 Aug 3;313(7052):275-83
pubmed: 8704542
PLoS Biol. 2018 Nov 20;16(11):e2006930
pubmed: 30457984
JAMA. 2000 Apr 26;283(16):2158-60
pubmed: 10791510
J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2600-2606
pubmed: 29531091
Lancet. 2014 Jan 18;383(9913):257-66
pubmed: 24411650
Nature. 2014 Jan 30;505(7485):612-3
pubmed: 24482835
BMJ. 2015 May 07;350:h2373
pubmed: 25953153
BMJ Open. 2011 Feb 26;1(1):e000048
pubmed: 22021739
JAMA. 1998 Jul 15;280(3):275-7
pubmed: 9676680
Nat Hum Behav. 2020 Jan;4(1):4-6
pubmed: 31792401
BMJ. 2018 Feb 13;360:k400
pubmed: 29440066
N Engl J Med. 2017 Mar 23;376(12):1178-1181
pubmed: 28328337
N Engl J Med. 1991 May 9;324(19):1362-5
pubmed: 1901959
N Engl J Med. 2016 Aug 4;375(5):403-5
pubmed: 27518657
Med Care. 2003 Jan;41(1):32-44
pubmed: 12544542
Pharmacoeconomics. 2018 Feb;36(2):253-257
pubmed: 29214388
Pharmacoeconomics. 2017 Jan;35(1):125-128
pubmed: 27928759
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
BMJ. 2017 Jul 20;358:j2998
pubmed: 28729459
Sci Transl Med. 2016 Jun 1;8(341):341ps12
pubmed: 27252173
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
PLoS Med. 2018 Sep 4;15(9):e1002663
pubmed: 30178782
PLoS Med. 2016 Jan 20;13(1):e1001950
pubmed: 26789528
N Engl J Med. 2017 Jan 19;376(3):203-205
pubmed: 28099837
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Lancet. 2014 Jan 11;383(9912):166-75
pubmed: 24411645
JAMA. 2018 Sep 4;320(9):937-938
pubmed: 30193273
JAMA. 2018 Apr 10;319(14):1429-1430
pubmed: 29566133
BMJ. 2013 Mar 25;346:f1049
pubmed: 23529982
Nature. 2015 Sep 3;525(7567):25-7
pubmed: 26333454
Ann Intern Med. 2017 Sep 19;167(6):432-433
pubmed: 28847014
BMJ. 2006 Mar 25;332(7543):699-703
pubmed: 16495332
J Clin Epidemiol. 2018 Feb;94:8-18
pubmed: 29113936
BMC Med. 2018 Dec 14;16(1):233
pubmed: 30545364
PLoS Biol. 2016 Jan 04;14(1):e1002333
pubmed: 26726926
Science. 2015 Jun 26;348(6242):1422-5
pubmed: 26113702
Med Decis Making. 2018 Oct;38(7):767-777
pubmed: 30248277
Int J Technol Assess Health Care. 2009 Oct;25(4):522-9
pubmed: 19845982